title: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.
abstract: Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
authors: Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, 53 Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
authors: Hirotaka
authors: H
authors: Ebina
authors: Naoko
authors: N
authors: Misawa
authors: Yuka
authors: Y
authors: Kanemura
authors: Yoshio
authors: Y
authors: Koyanagi
mesh_terms: D064130:CRISPR-Associated Proteins / Q000235:genetics*; D064113:CRISPR-Cas Systems; D020868:Gene Silencing; D057809:HEK293 Cells; D016325:HIV Long Terminal Repeat / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics* / Q000254:growth & development*; D006367:HeLa Cells; D006801:Humans; D017735:Virus Latency / Q000235:genetics*
chemical_list: D064130:CRISPR-Associated Proteins
references: Nature. 2005 Jun 2;435(7042):646-51
references: 15806097
references: Nat Biotechnol. 2011 Aug 05;29(8):699-700
references: 21822242
references: Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006890
references: 22762018
references: Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096
references: 22229121
references: J Virol. 1998 Oct;72(10):8150-7
references: 9733856
references: Nat Med. 2010 Mar;16(3):254-7
references: 20208503
references: J Genet Genomics. 2012 May 20;39(5):209-15
references: 22624882
references: AIDS Res Hum Retroviruses. 2007 Nov;23(11):1428-33
references: 18184086
references: Virus Genes. 2003 Oct;27(2):177-88
references: 14501196
references: Science. 2013 Feb 15;339(6121):819-23
references: 23287718
references: Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006916
references: 22355797
references: J Virol. 1998 Apr;72(4):2788-94
references: 9525598
references: Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2623-8
references: 21262818
references: Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2579-86
references: 22949671
references: Immunity. 2012 Sep 21;37(3):377-88
references: 22999944
references: Nature. 2012 Feb 15;482(7385):331-8
references: 22337052
references: Annu Rev Biochem. 2010;79:213-31
references: 20192761
references: EMBO J. 2003 Apr 15;22(8):1868-77
references: 12682019
references: Trends Biotechnol. 2013 Jul;31(7):397-405
references: 23664777
references: Nature. 2011 Sep 21;477(7365):486-489
references: 21938068
references: Biochemistry. 2002 May 21;41(20):6391-7
references: 12009901
references: Nat Biotechnol. 2013 Mar;31(3):230-2
references: 23360966
references: Nucleic Acids Res. 2013 Mar 1;41(5):e63
references: 23275534
references: Biol Direct. 2006 Mar 16;1:7
references: 16545108
references: Virology. 2012 May 25;427(1):44-50
references: 22374236
references: Biotechnol Bioeng. 2008 Jul 1;100(4):765-72
references: 18306419
references: Science. 2013 Feb 15;339(6121):823-6
references: 23287722
references: EMBO J. 2001 Apr 2;20(7):1726-38
references: 11285236